Method for treatment of neurodegenerative diseases and the effects of aging

Abstract

A method for treatment of neurodegenerative disease conditions stemming from multiple sclerosis, aging, autoimmune diseases and fibromyalgia. A compound effective to increase neuronal metabolism of histamine to a histamine H 2 agonist is administered in an amount sufficient to stimulate production of cyclic AMP at a level which is sufficient to maintain myelin against undergoing self-degeneration. The compound is selected from the group consisting of histamine M-methyltransferase, monoamineoxidase-A, monoamineoxidase-A agonists and histamine H 3 antagonists. The histamine M-methyltransferase may be administered to increase neuronal metabolism of histamine to tele-methylhistamine, whereas the monoamineoxidase-A or monoamineoxidase-A agonist may be administered so as to increase neuronal metabolism of telemethylhistamine to an H 2 agonist. Separately or in conjunction with the others, the histamine H 3 antagonist may be administered so as to inhibit metabolism of the telemethylhistamine to an H 3 agonist, thereby increasing metabolism of the telemethylhistamine to an H 2 agonist. The increased histamine H 2 agonist levels reduce demyelination and the symptoms that are associated with these conditions.

1 . A method for treatment of neurodegenerative conditions and effects of aging, including autoimmune conditions and fibromyalgia, said method comprising the steps of: 
 administering to a patient a compound effective for increasing neuronal metabolism of histamine to a histamine H2 agonist, in an amount sufficient that said histamine H2 agonist is produced in an amount adequate to stimulate production of cyclic AMP at a level which maintains myelin against undergoing self-degeneration.    
   
   
       2 . The method of  claim 1 , further comprising the step of: 
 selecting said compound from the group consisting of: 
 histamine N-methyltransferase;  
 monamine oxidase A;  
 monoamine oxidase-A agonists;  
 monoamine oxidase-B inhibitors;  
 histamine H3 antagonists; and  
 iron chelating agents.  
   
   
   
       3 . The method of  claim 2 , wherein said compound is histamine N-methyltransferase, and wherein the step of administering said compound comprises: 
 administering histamine N-methyltransferase to said patient so as to increase neuronal metabolism of histamine to tele-methylhistamine.    
   
   
       4 . The method of  claim 3 , wherein the step of administering histamine N-methyltransferase comprises: 
 administering isolated histamine N-methyltransferase by injection.